Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Problematic recommendations in ANN's guidelines on drug prevention of migraine.

  • Peer Carsten Tfelt-Hansen, Consultant, Department of neurology, Glostrup Hospital, Denmarkptha@regionh.dk
  • Peer Carsten Tfelt-Hansen
Submitted August 21, 2012

According to the recent AAN update guideline, a drug can be recommended as possibly effective for migraine prevention if it had demonstrated efficacy in one Class II study. [1]. Eight drugs are recommended as possibly effective [1]; and there are several drugs for which I would question the evidence. Due to space limitations, I will mention only one example. In the 2000 AAN Practice Parameter, [2] pindolol was in group 5 (evidence indicating no efficacy over placebo).This was based on two negative randomized, placebo-controlled trials. [3] It is unclear to me how pindolol is now listed in level C as possible effective. A possible explanation could be a re-analysis of an old comparative study of pindolol, clonidine and carbamazepine. [4] In a technical report [5] from1999 re-analyzing this study, [4] pindolol was reportedly superior to carbamazepine. However, this study was an open study and not a randomized, double-blind trial. [4] Pindolol has partial agonist activity [3] and this property is generally not compatible with preventive effect in migraine [3].

1.Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78: 1337-1345.

2.Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55: 754-762.

3.Tfelt-Hansen P, Rolan P. b-Adrenoceptor blocking drugs in migraine prophylaxis. In: Olesen J,Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 3rd Eds..Philadelphia York: Lippincott Williams & Wilkins 2006:519-528.

4.Anthony M, Lance JW, Sommerville B. A comparative trial of prindolol, clonidine and carbamazepine in the interval therapy of migraine. Med J Aust 1972; 1: 1343-1346.

5.Gray RN, Goslin RE, McCrory DC,et al. Drug Treatment for the Prevention of Migraine Headache. Technical Reviews, No. 2.3. Center for Clinical Health Policy Research, Duke University. Rockville (MD): Agency for Health Care Policy and Research (US): February 1999. Available from: http://www.ncbi.nlm.nih.gov/books/NBK45457/ (Assessed July 25 2012).

For disclosures, contact the editorial office at journal@neurology.org.

Navigate back to article

Neurology: 96 (8)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise